137 related articles for article (PubMed ID: 12400603)
1. Determination of plasma cell secreting potential as an index of maturity of myelomatous cells and a strong prognostic factor.
Symeonidis A; Kouraklis-Symeonidis A; Grouzi E; Zolota V; Melachrinou M; Kourea K; Fragopanagou E; Giannakoulas N; Seimeni U; Tiniakou M; Matsouka P; Zoumbos N
Leuk Lymphoma; 2002 Aug; 43(8):1605-12. PubMed ID: 12400603
[TBL] [Abstract][Full Text] [Related]
2. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
Pasqualetti P; Colantonio D; Collacciani A; Casale R; Natali G
Panminerva Med; 1991; 33(2):93-110. PubMed ID: 1923560
[TBL] [Abstract][Full Text] [Related]
3. A new staging system for multiple myeloma based on the number of S-phase plasma cells.
San Miguel JF; García-Sanz R; González M; Moro MJ; Hernández JM; Ortega F; Borrego D; Carnero M; Casanova F; Jiménez R
Blood; 1995 Jan; 85(2):448-55. PubMed ID: 7811998
[TBL] [Abstract][Full Text] [Related]
4. Biosynthesis of immunoglobulin in human immunoproliferative diseases. II. Comparison of tumour cell mass in multiple myeloma measured by synthetic rate studies with that calculated from clinical staging systems.
Cooper DA; Miller AC; Penny R
Acta Haematol; 1982; 68(3):224-36. PubMed ID: 6814151
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic factors in IgG and micromolecular multiple myeloma. Retrospective analysis of 50 consecutive cases].
Pasqualetti P; Casale R; Colantonio D; Festuccia V; Di Lauro G; Natali G
Minerva Med; 1987 May; 78(9):603-8. PubMed ID: 3587727
[TBL] [Abstract][Full Text] [Related]
6. Characterization of myeloma cells by means of labeling index, bone marrow histology, and serum beta 2-microglobulin.
Schambeck CM; Bartl R; Höchtlen-Vollmar W; Wick M; Lamerz R; Fateh-Moghadam A
Am J Clin Pathol; 1996 Jul; 106(1):64-8. PubMed ID: 8701935
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma.
Sahara N; Takeshita A; Shigeno K; Fujisawa S; Takeshita K; Naito K; Ihara M; Ono T; Tamashima S; Nara K; Ohnishi K; Ohno R
Br J Haematol; 2002 Jun; 117(4):882-5. PubMed ID: 12060125
[TBL] [Abstract][Full Text] [Related]
8. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
[TBL] [Abstract][Full Text] [Related]
9. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.
Ghermezi M; Li M; Vardanyan S; Harutyunyan NM; Gottlieb J; Berenson A; Spektor TM; Andreu-Vieyra C; Petraki S; Sanchez E; Udd K; Wang CS; Swift RA; Chen H; Berenson JR
Haematologica; 2017 Apr; 102(4):785-795. PubMed ID: 28034989
[TBL] [Abstract][Full Text] [Related]
10. [Utility of the examination of plasma-cell morphology in the study of multiple myeloma].
Moro MJ; Portero JA; Gascón A; Hernández JM; Ortega F; Jiménez R; Guerras L; Martínez M; Casanova F; Sanz MA
Sangre (Barc); 1992 Jun; 37(3):175-9. PubMed ID: 1440094
[TBL] [Abstract][Full Text] [Related]
11. A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients.
Merlini G; Waldenström JG; Jayakar SD
Blood; 1980 Jun; 55(6):1011-9. PubMed ID: 7378577
[TBL] [Abstract][Full Text] [Related]
12. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
[TBL] [Abstract][Full Text] [Related]
13. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
14. [A case report of multiple myeloma with marked Bence Jones proteinuria but slight serum mono component (IgG-kappa), showing lymphoid plasma cells in the bone marrow].
Hishitani Y; Shinoda K; Yasui T; Mozai T; Kanoh T; Yasuda N
Rinsho Ketsueki; 1984 Nov; 25(11):1831-6. PubMed ID: 6442739
[No Abstract] [Full Text] [Related]
15. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma.
Durie BG; Salmon SE; Moon TE
Blood; 1980 Mar; 55(3):364-72. PubMed ID: 7357075
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic value of the ratio of bone marrow plasma cells in multiple myeloma].
Pasqualetti P; Colantonio D; Casale R
Minerva Med; 1990 Mar; 81(3):129-33. PubMed ID: 2320280
[TBL] [Abstract][Full Text] [Related]
18. [Relation between certain parameters of renal function and prognosis in multiple myeloma].
Cengic M; Robovic Z; Rasic S; Golemac S
Med Arh; 2001; 55(4):193-5. PubMed ID: 11769440
[TBL] [Abstract][Full Text] [Related]
19. "Idiopathic" Bence Jones proteinuria: long-term follow-up in seven patients.
Kyle RA; Greipp PR
N Engl J Med; 1982 Mar; 306(10):564-7. PubMed ID: 7057813
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging.
Bartl R; Frisch B; Burkhardt R; Fateh-Moghadam A; Mahl G; Gierster P; Sund M; Kettner G
Br J Haematol; 1982 Jul; 51(3):361-75. PubMed ID: 7104223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]